# | Title | Journal | Year | Citations |
---|
1 | Ferroptosis, a new form of cell death: opportunities and challenges in cancer | Journal of Hematology and Oncology | 2019 | 924 |
2 | S100A8/A9 in Inflammation | Frontiers in Immunology | 2018 | 833 |
3 | Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape | Molecular Cancer | 2019 | 810 |
4 | The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression | Cell Research | 2020 | 616 |
5 | Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study | Lancet Oncology, The | 2021 | 459 |
6 | Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study | Lancet Oncology, The | 2018 | 436 |
7 | Neoantigen vaccine: an emerging tumor immunotherapy | Molecular Cancer | 2019 | 398 |
8 | Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial | Lancet Oncology, The | 2013 | 389 |
9 | Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer | JAMA Oncology | 2018 | 388 |
10 | The cancer metabolic reprogramming and immune response | Molecular Cancer | 2021 | 387 |
11 | The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine | Stem Cell Research and Therapy | 2019 | 386 |
12 | Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial | Lancet Oncology, The | 2020 | 373 |
13 | Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients | Clinical Cancer Research | 2018 | 357 |
14 | TGF-β induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype | Oncotarget | 2016 | 353 |
15 | Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT | Molecular Cancer | 2019 | 350 |
16 | Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial | Clinical Cancer Research | 2021 | 334 |
17 | Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA | Molecular Cancer | 2020 | 330 |
18 | Circular RNAs in human cancer | Molecular Cancer | 2017 | 310 |
19 | Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma | JAMA - Journal of the American Medical Association | 2021 | 310 |
20 | <p>Antibacterial activity and mechanism of silver nanoparticles against multidrug-resistant <em>Pseudomonas aeruginosa</em></p> | International Journal of Nanomedicine | 2019 | 297 |
21 | Role of metabolism in cancer cell radioresistance and radiosensitization methods | Journal of Experimental and Clinical Cancer Research | 2018 | 288 |
22 | Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers | Molecular Cancer | 2019 | 282 |
23 | Weakly Supervised Deep Learning for COVID-19 Infection Detection and Classification From CT Images | IEEE Access | 2020 | 279 |
24 | circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a | Journal of Experimental and Clinical Cancer Research | 2017 | 277 |
25 | Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial | Lancet Respiratory Medicine,the | 2021 | 277 |
26 | The role of microenvironment in tumor angiogenesis | Journal of Experimental and Clinical Cancer Research | 2020 | 276 |
27 | Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial | Journal of Thoracic Oncology | 2019 | 260 |
28 | The relationship between autophagy and the immune system and its applications for tumor immunotherapy | Molecular Cancer | 2019 | 239 |
29 | PARP inhibitor resistance: the underlying mechanisms and clinical implications | Molecular Cancer | 2020 | 235 |
30 | Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study | Journal of Clinical Oncology | 2019 | 226 |
31 | Pyroptosis: a new paradigm of cell death for fighting against cancer | Journal of Experimental and Clinical Cancer Research | 2021 | 224 |
32 | Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma | Oncotarget | 2015 | 210 |
33 | Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial | Nature Medicine | 2021 | 197 |
34 | Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) | British Journal of Cancer | 2018 | 192 |
35 | Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial | Lancet Oncology, The | 2021 | 188 |
36 | Neutrophil extracellular traps are indirectly triggered by lipopolysaccharide and contribute to acute lung injury | Scientific Reports | 2016 | 185 |
37 | Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy | Molecular Cancer | 2020 | 180 |
38 | Cancer stem cells in progression of colorectal cancer | Oncotarget | 2018 | 179 |
39 | Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments | Molecular Cancer | 2021 | 177 |
40 | Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial | Cancer Cell | 2022 | 177 |
41 | CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expression | Cell Death and Disease | 2019 | 171 |
42 | Ferroptosis, radiotherapy, and combination therapeutic strategies | Protein and Cell | 2021 | 167 |
43 | Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial | Journal of Clinical Oncology | 2021 | 159 |
44 | Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12) | Journal of Thoracic Oncology | 2021 | 158 |
45 | Chronic Stress Promotes Cancer Development | Frontiers in Oncology | 2020 | 157 |
46 | Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China | Journal of Hematology and Oncology | 2017 | 155 |
47 | Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: Role of renin-angiotensin system | Redox Biology | 2019 | 155 |
48 | Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2019 | 154 |
49 | Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract | Frontiers in Immunology | 2020 | 152 |
50 | Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study | Blood | 2015 | 150 |